Is Cogent Biosciences, Inc. (COGT) a Buy, Sell, or Hold?
NASDAQ : COGT
Cogent Biosciences, Inc.
$39.1408 USD
$1.2 (3.16%)
- Volume
- 771.97K
- Average Volume
- 2.42M
- Market Capitalization
- $6.69B
- P/E Ratio
- -12.71
- Dividend Yield
- 0.00%
- Price Target
- $48.50
- Year High
- $43.73
- Year Low
- $10.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.14
Insider Activity Summary (Last 12 Months)
Insiders Buying
31
Insiders Selling
14
Amount of Insider Selling
$12.03M
COGT Insider Buying/Selling by Quarter
COGT Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Ferrante Karen Jean | director | 2026-07-01 | A-Award | 38.48 | 2026-07-06 |
| Harwin Peter Evan | director | 2026-06-09 | A-Award | 31.98 | 2026-06-11 |
| Ferrante Karen Jean | director | 2026-06-09 | A-Award | 31.98 | 2026-06-11 |
| CAIN CHRISTOPHER W. | director | 2026-06-09 | A-Award | 31.98 | 2026-06-11 |
| Shegog Todd | director | 2026-06-09 | A-Award | 31.98 | 2026-06-11 |
| Morris Arlene | director | 2026-06-09 | A-Award | 31.98 | 2026-06-11 |
| Ros Matthew | director | 2026-06-09 | A-Award | 31.98 | 2026-06-11 |
| Robbins Andrew R | director, officer: President and CEO | 2026-05-19 | G-Gift | 0 | 2026-05-21 |
| Robbins Andrew R | director, officer: President and CEO | 2026-05-19 | G-Gift | 0 | 2026-05-21 |
| Ferrante Karen Jean | director | 2026-04-01 | A-Award | 35.24 | 2026-04-03 |
| Fairmount Funds Management LLC | director | 2026-03-31 | C-Conversion | 0 | 2026-03-31 |
| Fairmount Funds Management LLC | director | 2026-03-31 | S-Sale | 34.66 | 2026-03-31 |
| Fairmount Funds Management LLC | director | 2026-03-31 | C-Conversion | 0 | 2026-03-31 |
| Fairmount Funds Management LLC | director | 2026-01-22 | S-Sale | 36.4 | 2026-01-22 |
| Ferrante Karen Jean | director | 2026-01-01 | A-Award | 34.74 | 2026-01-05 |
| Kearns Evan | officer: Chief Legal Officer | 2025-12-26 | S-Sale | 38.7 | 2025-12-30 |
| Green John L. | officer: Chief Financial Officer | 2025-12-26 | S-Sale | 38.68 | 2025-12-30 |
| Sachs Jessica | officer: Chief Medical Officer | 2025-12-26 | S-Sale | 38.7 | 2025-12-30 |
| Robinson John Edward | officer: Chief Scientific Officer | 2025-12-26 | S-Sale | 38.74 | 2025-12-30 |
| Robinson John Edward | officer: Chief Scientific Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Robinson John Edward | officer: Chief Scientific Officer | 2025-12-17 | F-InKind | 39.45 | 2025-12-19 |
| Robinson John Edward | officer: Chief Scientific Officer | 2025-12-17 | A-Award | 39.45 | 2025-12-19 |
| Robinson John Edward | officer: Chief Scientific Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Robbins Andrew R | director, officer: President and CEO | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Robbins Andrew R | director, officer: President and CEO | 2025-12-17 | F-InKind | 39.45 | 2025-12-19 |
| Robbins Andrew R | director, officer: President and CEO | 2025-12-17 | A-Award | 39.45 | 2025-12-19 |
| Robbins Andrew R | director, officer: President and CEO | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Pinnow Cole | officer: Chief Commercial Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Pinnow Cole | officer: Chief Commercial Officer | 2025-12-17 | F-InKind | 39.45 | 2025-12-19 |
| Pinnow Cole | officer: Chief Commercial Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Pinnow Cole | officer: Chief Commercial Officer | 2025-12-17 | A-Award | 39.45 | 2025-12-19 |
| Kearns Evan | officer: Chief Legal Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Kearns Evan | officer: Chief Legal Officer | 2025-12-17 | F-InKind | 39.45 | 2025-12-19 |
| Kearns Evan | officer: Chief Legal Officer | 2025-12-17 | A-Award | 39.45 | 2025-12-19 |
| Kearns Evan | officer: Chief Legal Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Sachs Jessica | officer: Chief Medical Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Sachs Jessica | officer: Chief Medical Officer | 2025-12-17 | F-InKind | 39.45 | 2025-12-19 |
| Sachs Jessica | officer: Chief Medical Officer | 2025-12-17 | A-Award | 39.45 | 2025-12-19 |
| Sachs Jessica | officer: Chief Medical Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Green John L. | officer: Chief Financial Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Green John L. | officer: Chief Financial Officer | 2025-12-17 | F-InKind | 39.45 | 2025-12-19 |
| Green John L. | officer: Chief Financial Officer | 2025-12-17 | A-Award | 39.45 | 2025-12-19 |
| Green John L. | officer: Chief Financial Officer | 2025-12-17 | A-Award | 0 | 2025-12-19 |
| Ferrante Karen Jean | director | 2025-10-01 | A-Award | 14.13 | 2025-10-03 |
| Fairmount Funds Management LLC | director | 2025-07-10 | P-Purchase | 9 | 2025-07-14 |
| Ferrante Karen Jean | director | 2025-07-01 | A-Award | 7.22 | 2025-07-02 |
| Ferrante Karen Jean | director | 2025-06-04 | A-Award | 5.64 | 2025-06-05 |
| CAIN CHRISTOPHER W. | director | 2025-06-04 | A-Award | 5.64 | 2025-06-05 |
| Ros Matthew | director | 2025-06-04 | A-Award | 5.64 | 2025-06-05 |
| Shegog Todd | director | 2025-06-04 | A-Award | 5.64 | 2025-06-05 |
| Harwin Peter Evan | director | 2025-06-04 | A-Award | 5.64 | 2025-06-05 |
| Morris Arlene | director | 2025-06-04 | A-Award | 5.64 | 2025-06-05 |
| Ferrante Karen Jean | director | 2025-04-01 | A-Award | 5.79 | 2025-04-03 |
| Green John L. | officer: Chief Financial Officer | 2025-01-23 | A-Award | 8.89 | 2025-01-27 |
| Pinnow Cole | officer: Chief Commercial Officer | 2025-01-23 | A-Award | 8.89 | 2025-01-27 |
| Robinson John Edward | officer: Chief Scientific Officer | 2025-01-23 | A-Award | 8.89 | 2025-01-27 |
| Sachs Jessica | officer: Chief Medical Officer | 2025-01-23 | A-Award | 8.89 | 2025-01-27 |
| Robbins Andrew R | director, officer: President and CEO | 2025-01-23 | A-Award | 8.89 | 2025-01-27 |
| Kearns Evan | officer: Chief Legal Officer | 2025-01-23 | A-Award | 8.89 | 2025-01-27 |
| Pinnow Cole | officer: Chief Commercial Officer | 2025-01-14 | P-Purchase | 7.598 | 2025-01-15 |
| Ferrante Karen Jean | director | 2025-01-01 | A-Award | 7.8 | 2025-01-03 |
| Ferrante Karen Jean | director | 2024-10-01 | A-Award | 10.75 | 2024-10-02 |
| Ferrante Karen Jean | director | 2024-07-01 | A-Award | 8.94 | 2024-07-02 |
| CAIN CHRISTOPHER W. | director | 2024-06-05 | A-Award | 8.92 | 2024-06-13 |
| Ros Matthew | director | 2024-06-05 | A-Award | 8.92 | 2024-06-13 |
| Ferrante Karen Jean | director | 2024-06-05 | A-Award | 8.92 | 2024-06-13 |
| Harwin Peter Evan | director | 2024-06-05 | A-Award | 8.92 | 2024-06-13 |
| Shegog Todd | director | 2024-06-05 | A-Award | 8.92 | 2024-06-13 |
| Morris Arlene | director | 2024-06-05 | A-Award | 8.92 | 2024-06-13 |
| Fairmount Funds Management LLC | director | 2024-06-10 | M-Exempt | 0.001 | 2024-06-12 |
| Fairmount Funds Management LLC | director | 2024-06-10 | M-Exempt | 0 | 2024-06-12 |
| Pinnow Cole | officer: Chief Commercial Officer | 2024-05-25 | A-Award | 8.22 | 2024-05-29 |
| Pinnow Cole | officer: Chief Commercial Officer | 2024-05-25 | 0 | 2024-05-29 | |
| Ferrante Karen Jean | director | 2024-04-01 | A-Award | 6.9 | 2024-04-02 |
| Fairmount Funds Management LLC | director | 2024-03-28 | J-Other | 0 | 2024-04-01 |
| Fairmount Funds Management LLC | director | 2024-03-28 | J-Other | 0 | 2024-04-01 |
| Fairmount Funds Management LLC | director | 2024-03-28 | J-Other | 0 | 2024-04-01 |
| Fairmount Funds Management LLC | director | 2024-03-28 | J-Other | 0 | 2024-04-01 |
| Fairmount Funds Management LLC | 10 percent owner | 2024-02-16 | A-Award | 7.5 | 2024-02-16 |
| Fairmount Funds Management LLC | 10 percent owner | 2024-02-16 | A-Award | 0 | 2024-02-16 |
| Robinson John Edward | officer: Chief Scientific Officer | 2024-01-23 | A-Award | 4.63 | 2024-01-25 |
| Kearns Evan | officer: Chief Legal Officer | 2024-01-23 | A-Award | 4.63 | 2024-01-25 |
| Sachs Jessica | officer: Chief Medical Officer | 2024-01-23 | A-Award | 4.63 | 2024-01-25 |
| Robbins Andrew R | director, officer: President and CEO | 2024-01-23 | A-Award | 4.63 | 2024-01-25 |
| Green John L. | officer: Chief Financial Officer | 2024-01-23 | A-Award | 4.63 | 2024-01-25 |
| Ferrante Karen Jean | director | 2024-01-02 | A-Award | 6.24 | 2024-01-04 |
| Ros Matthew | director | 2024-01-02 | A-Award | 6.24 | 2024-01-04 |
| Ros Matthew | director | 2023-10-02 | A-Award | 9.55 | 2023-10-03 |
| Ferrante Karen Jean | director | 2023-10-02 | A-Award | 9.55 | 2023-10-03 |
| Ferrante Karen Jean | director | 2023-07-03 | A-Award | 11.96 | 2023-07-05 |
| Ros Matthew | director | 2023-07-03 | A-Award | 11.96 | 2023-07-05 |
| Fairmount Funds Management LLC | 10 percent owner | 2023-06-09 | P-Purchase | 12 | 2023-06-13 |
| Morris Arlene | director | 2023-06-07 | A-Award | 11.7 | 2023-06-08 |
| CAIN CHRISTOPHER W. | director | 2023-06-07 | A-Award | 11.7 | 2023-06-08 |
| Ferrante Karen Jean | director | 2023-06-07 | A-Award | 11.7 | 2023-06-08 |
| Shegog Todd | director | 2023-06-07 | A-Award | 11.7 | 2023-06-08 |
| Ros Matthew | director | 2023-06-07 | A-Award | 11.7 | 2023-06-08 |
| Harwin Peter Evan | director | 2023-06-07 | A-Award | 11.7 | 2023-06-08 |
| Ferrante Karen Jean | director | 2023-04-03 | A-Award | 10.75 | 2023-04-04 |
| Ros Matthew | director | 2023-04-03 | A-Award | 10.75 | 2023-04-04 |